Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2023-12-06 00:00:00 ET · period of report 2023-12-04 · accession 0000950170-23-068650 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-06 | 2023-12-05+ | CORT | Robb Gary Charles | Chief Business Off | S - Sale+OE | $26.88 | -7,593 | 27.6K | -22% | -$204.1K |
| D | 2023-12-06 | 2023-12-04 | CORT | Robb Gary Charles | Chief Business Off | F - Tax | $26.26 | -8,788 | 29.0K | -23% | -$230.8K |
| D | 2023-12-06 | 2023-12-04 | CORT | Robb Gary Charles | Chief Business Off | M - OptEx | $3.29 | +15.0K | 37.8K | +66% | +$49.4K |
| D | 2023-12-06 | 2023-12-04 | CORT | Robb Gary Charles | Chief Business Off | M - OptEx | $0.00 | -15.0K | 61.0K | -20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-06 | S | D | 6,212 | $27.01 | 21,390 | D | — | — | (F1) Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2023-12-05 | S | D | 1,381 | $26.27 | 27,602 | D | — | — | (F1) Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 3 | Common | Common Stock | 2023-12-04 | F | D | 8,788 | $26.26 | 28,983 | D | — | — | (F1) Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 4 | Common | Common Stock | 2023-12-04 | M | A | 15,000 | $3.29 | 37,771 | D | — | — | (F1) Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 5 | Derivative | Stock option (right to buy) | 2023-12-04 | M | D | 15,000 | $0.00 | 61,037 | D | $3.29 · — to 2025-02-18 | 15,000 Common Stock | (F4) Fully exercisable. |